Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 3Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Neoplasm Metastasis 1Melanoma 1

Interventions

pembrolizumab 326Nivolumab 289Ipilimumab 260Cyclophosphamide 194aldesleukin 145Interleukin-2 109fludarabine phosphate 107Temozolomide 83fludarabine 81Dacarbazine 81Radiotherapy 74trametinib 73Vemurafenib 69dabrafenib 66Biopsy 65sargramostim 50Bevacizumab 50Radiosurgery 49Paclitaxel 49Peripheral Blood Stem Cell Transplantation 48Magnetic Resonance Spectroscopy 48Carboplatin 48Imiquimod 47Aminolevulinic Acid 47binimetinib 45Cisplatin 45CTLA-4 Antigen 43cemiplimab 42Specimen Handling 42atezolizumab 41

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Histamine × Dermatologic × Clear all
NCT00039234 2013-12-18

Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Stage IV Melanoma Metastatic to the Liver

National Cancer Institute (NCI)

Phase 3 Unknown
Dermatologic

Melanoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡